AstraZeneca Says First Dose of Its Covid-19 Vaccine Induces Immunity for at Least One Year
June 28 2021 - 10:43AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that trials on its Vaxzevria
Covid-19 vaccine demonstrated strong immune responses following a
prolonged second dose interval of up to 45 weeks.
The pharmaceutical company said antibody levels remain elevated
for at least one year following a single dose.
AstraZeneca said a longer dosing interval isn't detrimental, but
can derive stronger immunity as the level of antibodies were found
to be four times higher with a 45-week dosing interval than with a
12-week interval.
A third dose given at least six months after the second boosted
antibody levels six-fold, maintained T cell response, and resulted
in neutralizing activity against the Alpha, Beta and Delta
variants, it said.
"This should come as reassuring news to countries with lower
supplies of the vaccine, who may be concerned about delays in
providing second doses to their populations. There is an excellent
response to a second dose, even after a 10 month delay from the
first," said Andrew J Pollard, chief investigator and director of
the Oxford Vaccine Group.
Shares in AstraZeneca at 1410 GMT were up 130 pence, or 1.5%, at
8,629 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
June 28, 2021 10:32 ET (14:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
